Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Feb 28, 2025
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study --
Read more at globenewswire.com48.37
-0.48 (-0.98%)
Find more stocks in the Stock Screener
AKRO Latest News and Analysis
15 days ago - By: Chartmill
